Oxford BA: Patents Exam Paper

InnovateCorp has developed a revolutionary new pharmaceutical compound, 'MediHeal', which treats a rare genetic disorder. The compound's molecular structure is entirely novel, requiring five years of research and £50 million investment. Before filing for a patent, a laboratory technician, Sarah, leaves InnovateCorp and joins RivalPharm Ltd. Sarah does not disclose MediHeal's formula but suggests RivalPharm research similar molecular pathways. Six months later, RivalPharm independently develops 'CureMax', which has an identical therapeutic effect to MediHeal but uses a different molecular structure achieving the same biological mechanism. InnovateCorp files for a UK patent on MediHeal, claiming the specific compound and 'pharmaceutical compositions for treating genetic disorder X by inhibiting protein Y'. RivalPharm argues InnovateCorp's patent application is invalid due to insufficient disclosure and that their CureMax does not infringe. InnovateCorp also discovers that a Japanese research paper published two years ago described a theoretical compound with MediHeal's exact structure, though it was never synthesized or tested. Advise InnovateCorp on the validity of their patent and prospects for infringement proceedings against RivalPharm.

Critically evaluate the extent to which the current approach to patentability of computer-implemented inventions in the UK adequately balances innovation incentives with the public interest in preventing monopolization of abstract ideas and mathematical concepts.

TechnoMed Ltd holds a patent for a 'method of treating diabetes using continuous glucose monitoring combined with automated insulin delivery' (Patent A). The patent claims both the method and the device implementing it. DrugCorp has developed 'GlucoFree', a drug that eliminates the need for insulin in 60% of diabetes patients by regenerating pancreatic cells. GlucoFree requires initial treatment using continuous glucose monitoring identical to TechnoMed's patented device, but patients subsequently need no further medical intervention. TechnoMed argues this constitutes infringement of both their method and device claims. DrugCorp contends that their use is exempt under s.60(5)(a) as experimental use, since monitoring is necessary to establish treatment efficacy and safety in individual patients. Additionally, MediGeneric Ltd wishes to conduct clinical trials on a generic version of GlucoFree, using TechnoMed's monitoring system throughout the trial period. Hospital NHS Trust also uses TechnoMed's device for treating patients but argues NHS use should be exempt from patent infringement. Finally, TechnoMed's patent is due to expire next year, and they seek to file a Supplementary Protection Certificate (SPC) claiming their device is essential for administering newly approved drugs. Advise all parties on their respective positions regarding patent infringement and available defenses.

To what extent does the current patent system adequately address the challenges posed by AI-generated inventions, particularly regarding inventorship requirements and the fundamental justifications for patent protection?